^
Association details:
| Biomarker: | DCTN1-ALK rearrangement + ALK-CLIP4 rearrangement |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements
Published date:
02/24/2022
Excerpt:
...we report a 46-year-old female who was diagnosed with lung adenocarcinoma and identified carrying concurrent DCTN1-ALK and ALK-CLIP4 rearrangements by next generation sequencing (NGS) (638-gene panel). This patient showed partial response to crizotinib with a progress-free survival of 12 months
DOI:
https://doi.org/10.1111/1759-7714.14345
